Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages e1-e11

  Zeichner, Simon B ^a   Koru Sengul, Tulay ^d,f   Shah, Nikesh ^d   Liu, Qingyun ^e   Markward, Nathan J ^b   Montero, Alberto J ^c   Glück, Stefan ^d,f   Silva, Orlando ^d,f   Ahn, Eugene R ^d,f  

^a EMORY UNIVERSITY   (United States)

^b UNITED HEALTHCARE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Department of Biology   (United States)

^f UNIVERSITY OF MIAMI   (United States)

Author keywords

Calcitriol; ErbB2 AKT ERK pathway; Pleiotropic effects; Trastuzumab; Vitamin D receptor; Vitamin D supplementation

Indexed keywords

25 HYDROXYVITAMIN D; ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TAXANE DERIVATIVE; TRASTUZUMAB; VITAMIN D RECEPTOR; ERBB2 PROTEIN, HUMAN; VITAMIN D;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PLEIOTROPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VOLUME; VITAMIN SUPPLEMENTATION; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; DIET SUPPLEMENTATION; DIET THERAPY; FOLLOW UP; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIETARY SUPPLEMENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN D;

EID: 84920271739     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.08.001     Document Type: Article

References (52)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Fact Sheets: Breast Cancer. Available at: http://seer.cancer.gov/statfacts/html/breast.html. Accessed: January 12, 2014.
2. U. Zurawska, D.A. Baribeau, and S. Giilck Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients Curr Oncol 20 2013 e539 e545
3. A.V. Krishnan, S. Swami, and D. Feldman The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer Steroids 77 2012 1107 1112
4. H.J. Lee, J.Y. So, and A. DeCastro Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling J Steroid Biochem Mol Biol 121 2010 408 412
5. S. Abbas, J. Linseisen, and T. Slanger Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer - results of a large case-control study Carcinogenesis 29 2008 93 99
6. E.R. Bertone-Johnson, W.Y. Chen, and M.F. Holick Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer Cancer Epidemiol Biomarkers Prev 14 2005 1991 1997
7. L.C. Lowe, M. Guy, and J.L. Mansi Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population Eur J Cancer 41 2005 1164 1169
8. E.M. Poole, X. Shu, and B.J. Caan Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project Breast Cancer Res Treat 139 2013 529 537
9. M. Chung, J. Lee, and T. Terasawa Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force Ann Intern Med 155 2011 827
10. E.T. Jacobs, C.A. Thomson, and S.W. Flatt Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study Am J Clin Nutr 93 2011 108 117
11. A.C. Wolff, H. Hammond, and D.G. Hicks Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 2013 3997 4013
12. L. Livi, I. Meattini, and C. Saieva Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer Cancer 118 2012 3236 3243
13. M.P. Banegas, and C.I. Li Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women Breast Cancer Res Treat 134 2012 1297 1304
14. W.A. Woodward, E.H. Huang, and M.D. McNeese African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy Cancer 107 2006 2662 2668
15. J.C. Livaudais, D.L. Hershman, and L. Habel Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer Breast Cancer Res Treat 131 2012 607 617
16. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
17. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC, 2013. Available at: http://nof.org/files/nof/public/content/file/917/upload/481.pdf. Accessed: January 12, 2014.
18. F. Sperati, P. Vici, and M. Maugeri-Saccà Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials PLoS One 8 2013 e69269
19. A. Porojnicu, T.E. Robsahm, and J.P. Berg Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin D may be involved: a possible role of sun-induced vitamin D J Steroid Biochem Mol Biol 103 2007 675 678
20. A.C. Porojnicu, Z. Lagunova, and T.E. Robsahm Changes in risk of death from breast cancer with season and latitude: sun exposure and breast cancer survival in Norway Breast Cancer Res Treat 102 2007 323 328
21. T.E. Robsahm, S. Tretli, and A. Dahlback Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway) Cancer Causes Control 15 2004 149 158
22. P.J. Goodwin, M. Ennis, K.I. Pritchard, J. Koo, and N. Hood Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer J Clin Oncol 27 2009 3757 3763
23. S. Hatse, D. Lambrechts, and A. Verstuyf Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency Carcinogenesis 33 2012 1319 1326
24. H.J. Kim, Y.M. Lee, and B.S. Ko Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer Ann Surg Oncol 18 2011 1830 1836
25. K.D. Crew Vitamin d: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol 2013 2013 483687
26. K.W. Colston, and C.M. Hansen Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer Endocr Relat Cancer 9 2002 45 59
27. J. Welsh Vitamin D and breast cancer: insights from animal models Am J Clin Nutr 80 2004 1721S 1724S
28. M.D. Althuis, J.H. Fergenbaum, M. Garcia-Closas, L.A. Brinton, M.P. Madigan, and M.E. Sherman Etiology of hormone receptor-defined breast cancer: a systematic review of the literature Cancer Epidemiol Biomarkers Prev 13 2004 1558 1568
29. J. Thorne, and M.J. Campbell The molecular cancer biology of the VDR D.L. Trump, C.S. Johnson, Vitamin D and Cancer 2011 Springer New York, NY 25 52
30. M. Pande, P.A. Thompson, and K.A. Do Genetic variants in the vitamin D pathway and breast cancer disease-free survival Carcinogenesis 34 2013 587 594
31. S. Swami, A.V. Krishnan, and D. Feldman 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cance cells Clin Cancer Res 6 2000 3371 3379
32. A. Stoica, M. Saceda, A. Fakhro, H.B. Solomon, B.D. Fenster, and M.B. Martin Regulation of estrogen receptor-alpha gene expression by 1, 25-dihydroxyvitamin D in MCF-7 cells J Cell Biochem 75 1999 640 651
33. A.V. Krishnan, S. Swami, L. Peng, J. Wang, J. Moreno, and D. Feldman Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy Endocrinology 151 2010 32 42
34. F.S. Fan, and W.C. Yu 1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line Cancer Invest 13 1995 280 286
35. S.S. Jensen, M.W. Madsen, J. Lukas, L. Binderup, and J. Bartek Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery Mol Endocrinol 15 2001 1370 1380
36. M. Simboli-Campbell, C.J. Narvaez, K. van Weelden, M. Tenniswood, and J. Welsh Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells Breast Cancer Res Treat 42 1997 31 41
37. Q. Wang, D. Lee, and V. Sysounthone 1,25-dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects Breast Cancer Res Treat 67 2001 157 168
38. K. Koli, and J. Keski-Oja 1Alpha,25-dihydroxyvitamin D3 and its analogues downregulate cell invasion-associated proteases in cultured malignant cells Cell Growth Differ 11 2000 221 229
39. D.J. Mantell, P.E. Owens, N.J. Bundred, E.B. Mawer, and A.E. Canfield 1α,25-Dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo Circ Res 87 2000 214 220
40. W. Brueggemeier, A.L. Quinn, M.L. Parrett, F.S. Joarder, R.E. Harris, and F.M. Robertson Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens Cancer Lett 140 1999 27 35
41. A.M.H. Brodie, Q. Lu, and B.J. Long Aromatase and COX- 2 expression in human breast cancers J Steroid Biochem Mol Biol 79 2001 41 47
42. A. Ristimaki, A. Sivula, and J. Lundin Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer Cancer Res 62 2002 632 635
43. G.G. Schwartz, L.W. Whitlatch, T.C. Chen, B.L. Lokeshwar, and M.F. Holick Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3 Cancer Epidemiol Biomarkers Prev 7 1998 391 395
44. K. Koshizuka, M. Koike, and H. Asou Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo Breast Cancer Res Treat 53 1999 113 120
45. Y. Ma, W.D. Yu, and P.A. Hershberger 1α,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model Mol Cancer Ther 7 2008 3047 3055
46. M. Chaudhary, S. Sundaram, C. Gennings, H.D. Carter, and A. Gewirtz The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells Cancer Chemother Pharmacol 47 2001 429 436
47. S. Yao, G. Zirpoli, and D.H. Bovbjerg Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study Breast Cancer Res 14 2012 R58
48. D. Slamon, W. Eiermann, and N. Robert Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
49. D. Slamon, S. Swain, M. Buyse, et al., Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH). Thirty-sixth Annual San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, TX.
50. S. Zeichner, C.G. Mihos, and O. Santana The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review J Cancer Res Ther 8 2012 176 183
51. S.M. Hadad, D.G. Hardie, V. Appleyard, and A.M. Thompson Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle Clin Transl Oncol 16 2014 746 752
52. B. Petricevic, J. Laengle, and J. Singer Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients J Transl Med 11 2013 307